Eli Lilly Dives On Earnings Miss As Diabetes, Weight-Loss Drugs Fall Short

Eli Lilly Dives On Earnings Miss As Diabetes, Weight-Loss Drugs Fall Short · Investor's Business Daily
ALLISON GATLIN
1 min read

In This Article:

Eli Lilly earnings and revenue missed Q3 views, with sales light for its diabetes and weight-loss drugs. Eli Lilly stock dived Wednesday.

Recommended Stories